cp 55,940 cp 55,940 cp 55,940 is a synthetic cannabinoid which mimics the effects of naturally occurring thc (one of the psychoactive compounds found in cannabis). cp 55,940 was created by pfizer in 1974 but was never marketed. it is currently used as a research tool to study the endocannabinoid system. cp 55,940legal statuslegal status ca: schedule ii identifiers iupac name 2--5-(2-methyloctan-2-yl)phenol cas number83002-04-4pubchem cid3086156chemspider94668uniikfy70972j5chemblchembl559612 ycomptox dashboard (epa)dtxsid80875516 chemical and physical dataformulac24h40o3molar mass376.581 g·mol−13d model (jsmol)interactive image smiles o1c(c2=cc=c(c(c)(c)cccccc)c=c2o)(ccco)cc1 inchi inchi=1s/c24h40o3/c1-4-5-6-7-14-24(2,3)19-11-13-21(23(27)16-19)22-17-20(26)12-10-18(22)9-8-15-25/h11,13,16,18,20,22,25-27h,4-10,12,14-15,17h2,1-3h3/t18-,20-,22-/m1/s1key:ynzffalzmraphq-syykkafvsa-n pharmacology cp 55,940 is 45 times more potent than δ9-thc, and fully antagonized by rimonabant (sr141716a). it is considered a full agonist at both cb1 and cb2 receptors and has ki values of 0.58 nm and 0.68 nm respectively, but is an antagonist at gpr55, the putative "cb3" receptor. cp 55,940 binding has been detected in the cytosol of rat brain cerebral cortex. it can upregulate 5-ht2a receptors in mice. in vitro studies cp 55,940 induced cell death in ng 108-15 mouse neuroblastoma x rat glioma hybrid brain cancer (genetically engineered mouse x rat brain cancer) cells. in vivo studies cp 55,940 showed protective effects on rat brain mitochondria upon paraquat exposure. it also showed neuroprotective effects by reducing intracellular calcium release and reducing hippocampal cell death in cultured neurons subjected to high levels of nmda.